DOCSLIB.ORG

Amgn-12.31.2019-10K Q4 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Amgn-12.31.2019-10K Q4 2019 2019 Letter to Shareholders | Amgen LETTER TO SHAREHOLDERS Robert A. Bradway, Chairman and Chief Executive Officer, Amgen Inc. To My Fellow Shareholders: As I write this letter, Amgen is us confidence that we can play an in our industry, which reflected our approaching a significant milestone: increasingly important role in the global ability to manage our efficiency and our 40th anniversary. The date was healthcare ecosystem. By doing so, we ongoing productivity gains. We invested April 8, 1980, when our founders are also confident that we can continue more than $4.0 billion1 in research established Applied Molecular Genetics to deliver on the commitments that we and development, up 10% from the (later shortened to Amgen) in Thousand make to you, our shareholders. prior year, as we advanced numerous Oaks, California, to explore new potential new medicines across all business opportunities made possible DELIVERING RESULTS stages of our pipeline. by the biotechnology revolution getting We also delivered an attractive underway at that time. As anticipated, total revenues decreased slightly in 2019 as double- return to our shareholders in 2019. Since then, we’ve seen hundreds of digit, volume-driven growth of many of Specifically, Amgen delivered a total biotech companies come and go as our newer medicines did not fully offset shareholder return of 28% last year, Amgen flourished. While Thousand the decline in sales of our off-patent exceeding the 19% average return Oaks still serves as our global legacy products, which faced increased of our peer group. Our five-year headquarters—and our original competition around the world. Total total shareholder return of 73% also building still stands—Amgen ranks revenues of $23.4 billion were down outpaced the average return of our today among the largest companies 2% from the prior year, with non- peer group, which delivered a 46% on the Fortune 500, with more than GAAP earnings per share rising 3% return over the same time period. 23,000 employees in 100 countries to a record $14.82.1 For the full year, Looking at an even longer investment around the world. Amgen achieved a non-GAAP operating horizon, a purchase of $10,000 of margin of 50.2%,1 among the highest Amgen stock the day the company We are proud of what we have accomplished—and eager to do more. We know that an aging global population will require innovative new Total Shareholder Return treatments for illnesses like cancer 2015–2019 and heart disease that claim millions Amgen of lives and cost society hundreds 73% of billions of dollars each year. The pioneering spirit of Amgen —a Amgen Peers 46% hallmark for four decades—gives 2 1This is a non-GAAP financial measure. See reconciliation to U.S. generally accepted accounting principles (GAAP) accompanying this letter. 2019 Letter to Shareholders | Amgen $23.4B $14.82 > $4B 50.2% 2019 Total Revenues Non-GAAP Non-GAAP Research and Non-GAAP Earnings Per Share1 Development Investment1 Operating Margin1 went public in 1983 would have been Strengthening Our Product Portfolio crisis affecting millions of people worth more than $8.6 million as of worldwide, especially women. The We have launched a number of new December 31, 2019, including the statistics are staggering. According medicines in recent years that treat reinvestment of dividends. Additionally, to the World Health Organization, some of the world’s most serious, in 2019, we returned more than one in three women worldwide over prevalent, and costly diseases. We $11 billion to shareholders in the form the age of 50 will suffer a fracture have been able to generate growth of dividends and share repurchases. due to osteoporosis. Each year in from these new products largely the U.S. alone, osteoporosis-related through volume gains, rather than RETURNING TO GROWTH fractures account for 432,000 hospital price increases. This is critical in admissions and 180,000 nursing 2019 was a challenging year and one an environment in which healthcare home admissions—and after the first for which we were prepared. Managing systems around the world are wrestling fracture, a woman is five times more the impact of patent expirations on with how to pay for the quality care likely to suffer another fracture within highly successful products is one that aging populations desire. a year. Amgen has been engaged in of the fundamental challenges that In 2019, for example, we launched the fight against osteoporosis for many all large companies in our industry ® EVENITY®, the first and only years with Prolia , our innovative, eventually face. I was pleased to osteoporosis treatment that both market-leading anti-resorptive therapy. report on an earnings call in January increases bone formation and reduces 2020 that we expect to return to bone loss, thereby rapidly reducing top-line growth this year. There are “The quality of our the risk of fracture. Osteoporosis a few factors driving our expected is a major public health people along with the resurgence, including our recently support of the medical launched products, our community have made Otezla® ongoing global expansion, the blockbuster brand it is today. It’s our robust pipeline clear that our Amgen colleagues possess of potential new the willingness to go beyond the scope of medicines, and our acquisition of their daily task and the competitive drive Otezla®. to deliver above expectations. Together, we will ultimately improve Otezla®’s impact on patients.” – Colley B., who joined Amgen through the Otezla® acquisition 1This is a non-GAAP financial measure. See reconciliation to U.S. generally accepted accounting principles (GAAP) accompanying this letter. 3 2019 Letter to Shareholders | Amgen in more than 50 countries, including 2019 HIGHLIGHT Amgen’s 10 largest markets. Through 2019 HIGHLIGHT the acquisition, we also welcomed ® Acquired Otezla , the only oral, more than 800 new employees to Launched first two biosimilars in non-biologic treatment for Amgen and haven’t missed a beat the U.S. to the cancer treatments psoriasis and psoriatic arthritis ® ® for the more than 400,000 patients Avastin and Herceptin worldwide who have been treated with EVENITY® gives us another weapon in Otezla®. We expect this product to be its original list price. This decision led this fight, and we are encouraged by a key growth driver for us in 2020 and to 20% sales growth in 2019 as more its early performance and long-term beyond. patients, especially senior citizens in potential. the Medicare program, were able to ® ® EVENITY and Otezla join a portfolio access this important medicine at a We further strengthened our product that includes six medicines that in more affordable co-pay. portfolio in 2019 through the $13.4 2019 each generated annual sales in billion acquisition of Otezla®, the excess of $500 million and grew at In addition to new innovative only oral, non-biologic treatment for high-single-digit or double-digit rates. medicines, we are strengthening psoriasis and psoriatic arthritis. Otezla® Repatha®, for example, is Amgen’s our product portfolio by leveraging bolsters our existing inflammation medicine for people with high LDL our decades of biomanufacturing franchise, which includes Enbrel®, our cholesterol who are at risk for heart experience to bring to patients largest product. Otezla® sales in 2019 attacks and strokes—devastating a reliable supply of high-quality totaled nearly $2 billion, with Amgen health events that occur every 40 biosimilars, which are typically priced booking $178 million of these sales seconds in the U.S. In 2018, to address below the originator medicines following the close of the acquisition in access challenges, we made Repatha® with which they compete. In 2019, late November. We acquired the global available in the U.S. at 60% less than AMGEVITA™, our biosimilar to the rights to Otezla®, which is approved autoimmune disease treatment “OneOncology’s trust in Amgen’s biosimilars is rooted in the company’s experience and manufacturing processes. Our decision to be an early MVASI™ and KANJINTI™ adopter is increasingly important to our strategy to deliver high-quality cancer care at lower costs, which benefits patients and payers alike.” – Dr. Jeffrey Patton, Acting Chief Executive Officer and President of Physician Services at OneOncology, a network of leading community cancer centers 4 2019 Letter to Shareholders | Amgen healthcare budgets that can be Expanding Our Geographic Presence 2019 HIGHLIGHT redirected toward our innovative medicines. As the number of For much of our 40-year history, Announced strategic biosimilars in our portfolio grows, we Amgen offered its medicines to collaboration to expand oncology are increasingly able to have more patients primarily in one market: the business in China and advance holistic conversations with healthcare U.S. Although the U.S. remains the our oncology pipeline globally systems about how best to care for world’s largest pharmaceutical market the patients they serve—and how —and therefore continues to be a top to pay for that care. For example, priority for Amgen—the rest of the Humira®, the world’s best-selling AMGEVITA™ is highly complementary world offers increasingly compelling medicine, generated more than to Otezla®, as both medicines treat opportunities to serve more patients $200 million in global sales. We also patients with chronic inflammatory and drive growth. We are especially launched our first two biosimilars in diseases. Similarly, MVASI™ and excited by our prospects in China the U.S., MVASI™ and KANJINTI™, KANJINTI™ complement the many and Japan, the world’s second- and which are biosimilars to the cancer innovative cancer medicines in our third-largest pharmaceutical markets, treatments Avastin® and Herceptin®, portfolio. In 2020, we plan to launch respectively. respectively. In total, Amgen biosimilars AVSOLA™, our biosimilar to the generated $568 million in 2019 In 2019, we announced a strategic inflammation treatment Remicade®, in sales and we believe these medicines collaboration with BeiGene—a the U.S., and we continue to advance represent a significant growth biotechnology company with a large several additional biosimilars through opportunity for us over time.
Load more

Recommended publications
  • Pharmacokinetics, Pharmacodynamics and Drug
    pharmaceutics Review Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies Danuta Szkutnik-Fiedler Department of Clinical Pharmacy and Biopharmacy, Pozna´nUniversity of Medical Sciences, Sw.´ Marii Magdaleny 14 St., 61-861 Pozna´n,Poland; [email protected] Received: 28 October 2020; Accepted: 30 November 2020; Published: 3 December 2020 Abstract: In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also in Europe. This publication reviews the available worldwide references on the safety of these anti-migraine drugs with a focus on the possible drug–drug (DDI) or drug–food interactions. As is known, bioavailability of a drug and, hence, its pharmacological efficacy depend on its pharmacokinetics and pharmacodynamics, which may be altered by drug interactions. This paper discusses the interactions of gepants and lasmiditan with, i.a., serotonergic drugs, CYP3A4 inhibitors, and inducers or breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) inhibitors. In the case of monoclonal antibodies, the issue of pharmacodynamic interactions related to the modulation of the immune system functions was addressed. It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR). Keywords: migraine; lasmiditan; gepants; monoclonal antibodies; drug–drug interactions 1. Introduction Migraine is a chronic neurological disorder characterized by a repetitive, usually unilateral, pulsating headache with attacks typically lasting from 4 to 72 h.
    [Show full text]
  • Pharmacy Prior Authorization Grid ALTCS, and Pharmacy
    Please Note: Refer to the other PA grids for applicable covered services that require PA. PA Grids: Medical, Behavioral Health, Pharmacy Prior Authorization Grid ALTCS, and Pharmacy. (Effective Date of Service 1/1/2021) Injectables that require Prior Authorization All chemotherapeutic drugs must be used for FDA-approved indications and/or in accordance with NCCN guidelines *Indicates prior authorization required if billed charges are greater than $400 PA Required HMO 13 HCPCS Short Description (BUCA- Code SNP) 90378 Respiratory Syncytial Virus Immune Globulin Yes C9036 Patisiran Yes C9047 Caplacizumab-yhdp Yes C9061 Teprotumumab-trbw Yes C9063 Eptinezumab-jjmr Yes C9131 Factor VIII antihemophilic factor pegylated-auci Yes C9132 Prothrombin Complex Concentrate (Human), Kcentra Yes C9133 Factor IX (Antihemophilic Factor, Recombinant), Rixibus Yes C9399 Mipomersen (Kynamro) Yes J0129 Abatacept Yes J0135 Adalimumab Yes J0178 Aflibercept Yes J0179 Brolucizumab-dbll, 1 mg Yes J0180 Agalsidase Beta Yes J0205 Alglucerase Yes J0215 Alefacept Yes J0220 Alglucosidase Alfa (Myozyme) Yes J0221 Alglucosidase Alfa (Lumizyme) Yes J0222 Patisiran, 0.1 mg Yes J0223 Givosiran 0.5 mg Yes J0256 Alpha 1-Proteinase Inhibitor Yes J0257 Alpha 1-Proteinase Inhibitor (Glassia) Yes J0275 Alprostadil Urethral Suppository Yes J0490 Belimumab Yes J0517 Benralizumab Yes J0567 Cerliponase alfa Yes J0570 Buprenorphine implant Yes J0584 Burosumab-twza 1 mg Yes J0585 Onabotulinumtoxina (Botox) Yes J0586 Abobotulinumtoxina (Dysport) Yes J0587 Rimabotulinumtoxinb (Myobloc)
    [Show full text]
  • Oxford Policy Update Bulletin: April 2020
    Oxford April 2020 policy update bulletin Medical & Administrative Policy Updates Take Note POLICY IMPLEMENTATION DELAYED Implementation of the changes associated with the following Clinical Policies, previously announced for an effective date on or after Apr. 1, 2020, has been delayed as noted below: Policy Title Status Effective Date Genitourinary Pathogen Nucleic Acid Detection Panel Testing New May 1, 2020 Jun. 1, 2020 Outpatient Surgical Procedures - Site of Service Revised Apr. 6, 2020 TBD Tysabri® (Natalizumab) New Apr. 1, 2020 Jul. 1, 2020 Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here. Policy Title Status Effective Date CLINICAL POLICY Abnormal Uterine Bleeding and Uterine Fibroids Revised Jun. 1, 2020 Actemra® (Tocilizumab) Injection for Intravenous Infusion Revised May 1, 2020 Adakveo® (Crizanlizumab-Tmca) Updated Apr. 1, 2020 Adakveo® (Crizanlizumab-Tmca) Revised Jul. 1, 2020 Cell-Free Fetal DNA Testing Revised Jun. 1, 2020 Cimzia® (Certolizumab Pegol) New Jul. 1, 2020 Collagen Crosslinks and Biochemical Markers of Bone Turnover Revised May 1, 2020 Drug Coverage Criteria – New and Therapeutic Equivalent Medications Revised May 1, 2020 Drug Coverage Guidelines Revised Apr. 1, 2020 Adakveo (Crizanlizumab-Tmca) Givlaari (Givosiran) Ziextenzo (Pegfilgrastim-Bmez) Drug Coverage Guidelines Revised May 1, 2020 Adlyxin (Lixisenatide) Arnuity
    [Show full text]
  • Alder Biopharmaceuticals, Inc. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36431 Alder BioPharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 90-0134860 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) 11804 North Creek Parkway South Bothell, WA 98011 (Address of principal executive offices including zip code) Registrant’s telephone number, including area code: (425) 205-2900 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
    [Show full text]
  • VYEPTI™ (EPTINEZUMAB) Policy Number: CSLA2020D0090A Effective Date: TBD
    Proprietary Information of United Healthcare: The information contained in this document is proprietary and the sole property of United HealthCare Services, Inc. Unauthorized copying, use and distribution of this information are strictly prohibited. Copyright 2020 United HealthCare Services, Inc. UnitedHealthcare® Community Plan Medical Benefit Drug Policy VYEPTI™ (EPTINEZUMAB) Policy Number: CSLA2020D0090A Effective Date: TBD Table of Contents Page Commercial Policy APPLICATION ...................................................... 1 Vyepti™ (Eptinezumab) COVERAGE RATIONALE ........................................ 1 APPLICABLE CODES ............................................. 2 BACKGROUND ................................................... 43 CLINICAL EVIDENCE ............................................ 4 U.S. FOOD AND DRUG ADMINISTRATION ............ 54 CENTERS FOR MEDICARE AND MEDICAID SERVICES 54 REFERENCES ....................................................... 5 POLICY HISTORY/REVISION INFORMATION ...... 65 INSTRUCTIONS FOR USE .................................... 65 APPLICATION This Medical Benefit Drug Policy only applies to state of Louisiana. COVERAGE RATIONALE Vyepti has been added to the Review at Launch program. Please reference the Medical Benefit Drug Policy titled Review at Launch for New to Market Medications for additional details. Chronic Migraine Vyepti is proven and medically necessary for the preventive treatment of chronic migraines when all of the following criteria are met: For initial therapy, all of the
    [Show full text]
  • 761119Orig1s000 SUMMARY REVIEW
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761119Orig1s000 SUMMARY REVIEW Summary Review Summary Review Date February 21, 2020 Heather Fitter, MD From Nick Kozauer, MD Billy Dunn, MD Subject Summary Review BLA # 761119 Applicant Lundbeck Seattle BioPharmaceuticals, Inc. Date of Submission December 26, 2018 PDUFA Goal Date February 21, 2020 Proprietary Name Vyepti Established or Proper Names Eptinezumab Solution for intravenous (IV) injection (100 Dosage Form mg/mL) Applicant Proposed Prevention of migraine in adults Indication/Population 100 mg IV infusion every 3 months; 300 mg IV Applicant Proposed Dosing Regimen(s) infusion every 3 months Recommendation on Regulatory Action Approval Recommended Indication/Population Preventive treatment of migraine in adults 100 mg IV infusion every 3 months; 300 mg IV Recommended Dosing Regimen(s) infusion every 3 months 1 Reference ID: 4564908 Summary Review 1. Benefit-Risk Assessment Benefit-Risk Assessment Framework Benefit-Risk Integrated Assessment Eptinezumab is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand, and prevents CGRP binding to its receptor. The applicant provided information supporting safety and efficacy in patients with both chronic migraine (i.e., at least 15 headache days/month, with features of migraine headache on at least 8 days/month) and episodic migraine (i.e., up to 14 migraine headache days/month). There are several FDA-approved drugs for the preventive treatment of migraine. Three drugs in the anti-CGRP class were approved recently for this indication: erenumab (May 2018), fremanezumab (September 2018), and galcanezumab (September 2018). These three drugs are given by subcutaneous (SC) administration either monthly or quarterly, while eptinezumab is given intravenously (IV) quarterly.
    [Show full text]
  • (CGRP) Inhibitor Criteria – Migraine and Cluster Headache Prevention Approval Date: February 24, 2021
    New Hampshire Medicaid Fee-for-Service Program Calcitonin Gene-Related Peptide (CGRP) Inhibitor Criteria – Migraine and Cluster Headache Prevention Approval Date: February 24, 2021 Medications Brand Names Generic Names Dosage 70 mg/mL solution single-dose prefilled syringe or auto-injector; Aimovig® erenumab-aooe 140 mg/mL prefilled syringe and autoinjector 225 mg/1.5 mL solution single-dose prefilled syringe; Ajovy® fremanezumab-vfrm 225 mg/1.5 mL autoinjector 120 mg/mL solution single-dose prefilled syringe or prefilled pen; Emgality® galcanezumab-gnlm 100 mg/mL solution single-dose prefilled syringe Vyepti™ eptinezumab-jjmr Intravenous (IV) solution: 100 mg/mL Indication Aimovig® (erenumab-aooe): A high-affinity human immunoglobulin G2 (IgG2) monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor, is indicated for the preventative treatment of migraine in adults. Ajovy® (fremanezumab-vfrm): A human IgG2 monoclonal antibody that targets the CGRP receptor, is indicated for the preventative treatment of migraine in adults. Emgality® (galcanezumab-gnlm): A human immunoglobulin IgG4 monoclonal antibody that targets the CGRP ligand, is indicated for the preventative treatment of migraine and episodic cluster headaches in adults. Vyepti™ (eptinezumab-jjmr): A humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the CGRP ligand and inhibits its interaction with the receptor, is indicated for the preventative treatment of migraine in adults. Proprietary & Confidential © 2003–2021 Magellan Health, Inc. All rights reserved. Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc. Migraine Headache Prevention Request Criteria for Approval 1. Patient has a diagnosis of migraine with or without aura based on International Classification of Headache Disorders (ICHD-III) diagnostic criteria; AND 2.
    [Show full text]
  • Monoclonal Antibodies As Neurological Therapeutics
    pharmaceuticals Review Monoclonal Antibodies as Neurological Therapeutics Panagiotis Gklinos 1 , Miranta Papadopoulou 2, Vid Stanulovic 3, Dimos D. Mitsikostas 4 and Dimitrios Papadopoulos 5,6,* 1 Department of Neurology, KAT General Hospital of Attica, 14561 Athens, Greece; [email protected] 2 Center for Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 11527 Athens, Greece; [email protected] 3 Global Pharmacovigilance, R&D Sanofi, 91385 Chilly-Mazarin, France; vid.stanulovic@sanofi.com 4 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 11521 Athens, Greece; [email protected] 5 Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 129 Vasilissis Sophias Avenue, 11521 Athens, Greece 6 Salpetriere Neuropsychiatric Clinic, 149 Papandreou Street, Metamorphosi, 14452 Athens, Greece * Correspondence: [email protected] Abstract: Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysio- logical mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of monoclonal antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these
    [Show full text]
  • Vyepti® (Eptinezumab-Jjmr) (Intravenous) Document Number: MAYO-0527 Last Review Date: 10/01/2020 Date of Origin: 04/01/2020 Dates Reviewed: 04/2020, 10/2020
    Vyepti® (eptinezumab-jjmr) (Intravenous) Document Number: MAYO-0527 Last Review Date: 10/01/2020 Date of Origin: 04/01/2020 Dates Reviewed: 04/2020, 10/2020 I. Length of Authorization Coverage will be provided for six months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Vyepti 100 mg/mL solution SDV: 3 vials per 84 days B. Max Units (per dose and over time) [HCPCS Unit]: − 300 billable units every 84 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: Universal Criteria 1,4-8 • Other causes of headaches have been ruled out; AND • Not used in combination with other calcitonin gene-related peptide (CGRP) antagonists (e.g., erenumab, galcanezumab, fremanezumab, etc.) §; AND • Patient will continue to utilize prophylactic intervention modalities (i.e., pharmacotherapy, behavioral therapy, physical therapy, etc.); AND • Physician has assessed baseline disease severity utilizing an objective measure/tool (e.g., Headache Impact Test [HIT]; monthly headache day [MHD]; Migraine Disability Assessment [MIDAS]; Migraine Physical Function Impact Diary [MPFID]); AND • Patient has failed at least an 8-week trial of any two oral medications for the prevention of migraines (see list of prophylactic medications below for examples) prior to initiation of eptinezumab; AND • Failure of or contraindication to use of a self-injected, prophylactic calcitonin gene-related peptide (CGRP) antagonists; AND § Note: Use with acute CGRP therapies (e.g., ubrogepant) is allowed Proprietary &
    [Show full text]
  • Anti‐Migraine Calcitonin Gene–Related Peptide Receptor
    RESEARCH ARTICLE Anti-migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice † † Inge A. Mulder, MSc ,1 Mei Li, PhD,1 Tessa de Vries, MSc,2 Tao Qin,1 , Takeshi Yanagisawa, MD, PhD,1 Kazutaka Sugimoto, MD, PhD ,1 Antoon van den Bogaerdt, PhD,3 A. H. Jan Danser, MD, PhD,2 Marieke J. H. Wermer, MD, PhD,4 Arn M. J. M. van den Maagdenberg, PhD,4,5 ‡ Antoinette MaassenVanDenBrink, PhD,2 Michel D. Ferrari, MD, PhD,4 and ‡ Cenk Ayata, MD, PhD1,6 Objective: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP- mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia. Methods: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes, collateral flow, and neurological deficits after pretreatment with olcegepant (single or 10 daily doses of 0.1–1mg/kg) or rimegepant (single doses of 10–100mg/kg) versus vehicle. We also determined their potency on CGRP-induced relaxa- tions in mouse and human vessels, in vitro. Results: Olcegepant (1mg/kg, single dose) increased infarct risk after 12- to 20-minute occlusions mimicking transient ischemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct volumes (p < 0.001) and worsened neurological deficits (median score = 9 vs 5 with vehicle, p = 0.008) after 60-minute occlusion. Ten daily doses of 0.1 to 1mg/kg olcegepant yielded similar results.
    [Show full text]
  • CDER List of Licensed Biological Products With
    Center for Drug Evaluation and Research List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date DATE OF FIRST REFERENCE PRODUCT DATE OF LICENSURE LICENSURE EXCLUSIVITY EXPIRY DATE INTERCHANGEABLE (I)/ BLA STN PRODUCT (PROPER) NAME PROPRIETARY NAME (mo/day/yr) (mo/day/yr) (mo/day/yr) BIOSIMILAR (B) WITHDRAWN 125118 abatacept Orencia 12/23/05 NA NA 103575 abciximab ReoPro 12/22/94 NA NA Yes 125274 abobotulinumtoxinA Dysport 04/29/09 125057 adalimumab Humira 12/31/02 NA NA 761071 adalimumab-adaz Hyrimoz 10/30/18 B 761058 adalimumab-adbm Cyltezo 08/25/17 B 761118 adalimumab-afzb Abrilada 11/15/19 B 761024 adalimumab-atto Amjevita 09/23/16 B 761059 adalimumab-bwwd Hadlima 07/23/19 B 125427 ado-trastuzumab emtansine Kadcyla 02/22/13 125387 aflibercept Eylea 11/18/11 103979 agalsidase beta Fabrazyme 04/24/03 NA NA 125431 albiglutide Tanzeum 04/15/14 017835 albumin chromated CR-51 serum Chromalbin 02/23/76 103293 aldesleukin Proleukin 05/05/92 NA NA 103948 alemtuzumab Campath, Lemtrada 05/07/01 NA NA 125141 alglucosidase alfa Myozyme 04/28/06 NA NA 125291 alglucosidase alfa Lumizyme 05/24/10 125559 alirocumab Praluent 07/24/15 103172 alteplase, cathflo activase Activase 11/13/87 NA NA 103950 anakinra Kineret 11/14/01 NA NA 020304 aprotinin Trasylol 12/29/93 125513 asfotase alfa Strensiq 10/23/15 101063 asparaginase Elspar 01/10/78 NA NA 125359 asparaginase erwinia chrysanthemi Erwinaze 11/18/11 761034 atezolizumab Tecentriq 05/18/16 761049 avelumab Bavencio 03/23/17
    [Show full text]
  • CGRP Inhibitors
    MEDICATION POLICY: CGRP Inhibitors Generic Name: N/A Preferred: Ajovy (fremanezumab-vfrm) Therapeutic or Brand Name: Calcitonin Gene- Non-preferred: Aimovig (Erenumab-aooe), Related Peptide (CGRP) Inhibitors Emgality (galcanezumab-gnlm), Nurtec (rimegepant), Ubrelvy (ubrogepant), Vypeti Applicable Drugs (if Therapeutic Class): (eptinezumab-jjmr) AimovigTM (Erenumab-aooe), AjovyTM (fremanezumab-vfrm), Emgality™ Date of Origin: 10/2/2018 (galcanezumab-gnlm), NurtecTM (rimegepant), Date Last Reviewed / Revised: 2/11/2021 Ubrelvy TM (ubrogepant), Vypeti TM (eptinezumab-jjmr) GPI Code: 6770202010, 6770203020, 6770203530, 6740654060, 6770108000, 6770201520 PRIOR AUTHORIZATION CRITERIA (May be considered medically necessary when criteria I through V are met) I. Documented diagnosis of one of the following conditions A or B and must meet criteria listed under applicable diagnosis: A. Episodic migraine headaches (4-14 migraine days per month) or chronic migraines (15 or more headache days per month with at least 8 migraine days per month) and criteria i – IV. Is met: i. Documentation of functional impairment due to episodic or chronic migraines (eg, severe pain, missed days at school or work, impaired activities of daily living). ii. Documentation of treatment failure, intolerance, or contraindication to medications from all 3 of the following drug categories A through C for prevention of episodic or chronic migraine headaches: 1. Anticonvulsants (such as Divalproex Sodium or Topiramate) 2. Beta-blockers (such as Metoprolol or propranolol) 3. Antidepressants (such as Venlafaxine or Amitriptyline) iii. Documentation that evaluation has been performed demonstrating patient does not suffer from rebound headaches due to medication overuse (medication overuse headache, or MOH). iv. Prescription is for Ajovy OR there is a clinically significant treatment failure, intolerance or contraindication to Ajovy and the prescription is for Aimovig, Emgality, or Vyepti.
    [Show full text]